UNITY uses next-generation DNA sequencing and deletion analysis of HBA1, HBA2, HBB, CFTR, and SMN1 to diagnose carrier status for cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies (alpha-thalassemia, beta-thalassemia, and sickle cell disease). Single nucleotide variants in the gene panel are identified by next-generation sequencing (NGS) of exons. Deletion analysis is performed by NGS and proprietary Quantitative Counting Template (QCT) technology. UNITY offers fetal risk assessment non-invasive prenatal testing (NIPT) of these single-gene disorders when a carrier is identified from pregnant, maternal blood. Single-gene NIPT is offered as an auto-reflex test that analyzes cell-free DNA (cfDNA) in blood plasma.